TDB Backs Chennai Firm to Boost Green Pharma Manufacturing

The company is working on a project focused on the manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their intermediates, and advanced drug liposome formulations.

India's efforts to strengthen self-reliance in pharmaceutical manufacturing have received another boost with the Technology Development Board (TDB), under the Department of Science and Technology (DST), extending support to Chennai-based Bioneemtec India Private Limited. The company is working on a project focused on the manufacturing of Minoxidil, Tranexamic Acid, Dequalinium Chloride, their intermediates, and advanced drug liposome formulations.

The initiative aims to bring homegrown green chemistry technologies into large-scale commercial production. The project is expected to reduce India's dependence on imported pharmaceutical ingredients while supporting cleaner and more efficient manufacturing practices.

Focus on Sustainable and Advanced Manufacturing

Bioneemtec plans to establish modern manufacturing facilities capable of producing pharmaceutical intermediates, Active Pharmaceutical Ingredients (APIs), and innovative drug delivery systems. The project will combine conventional batch production methods with advanced continuous-flow chemistry technologies, helping improve product quality, operational safety, and production efficiency.

One of the major highlights is the commercialization of an indigenous process for manufacturing Tranexamic Acid, a widely used medicine for treating bleeding disorders. The technology has been designed to deliver high-purity products through a cost-effective production route that generates less waste and reduces process complexity. The company will also manufacture Minoxidil and Dequalinium Chloride along with their key intermediates, creating stronger domestic supply chains for pharmaceutical products that currently rely heavily on imports.

Liposome Technology Opens New Opportunities

Beyond API manufacturing, the project includes the development of proprietary drug liposome formulations based on nanotechnology. These advanced drug delivery systems are being explored for applications in breast cancer and skin cancer treatment. According to the company, the formulations have shown encouraging results with controlled nanoparticle properties, which are critical for targeted drug delivery. Bioneemtec has already initiated intellectual property protection for these technologies, laying the groundwork for future innovation in next-generation therapeutics.

Speaking about the significance of the project, TDB Secretary Rajesh Kumar Pathak said that sustainable and technology-driven production systems will play a crucial role in the future of pharmaceutical manufacturing. He noted that indigenous development of advanced APIs, critical intermediates, and innovative drug delivery platforms will help strengthen India's position as a leading pharmaceutical manufacturing hub while supporting healthcare security.

The company welcomed the support from TDB, stating that it would accelerate the commercialization of its green chemistry technologies and advanced pharmaceutical products. The project is expected to create new opportunities in both domestic and international markets while reinforcing India's capabilities in high-value pharmaceutical manufacturing.